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Abstract
Introduction: Management	 of	 brain	 metastases	 (BMs)	 depends	 on	 important	
prognostic	factors	such	as	age,	performance	status	(PS),	primary	cancer	and	the	





the	 largest	BM	(≥	3	cm).	The	aim	was	 to	evaluate	 the	association	between	 the	
size	of	BM	and	overall	survival	(OS),	in	months,	and	the	second	outcome	was	to	



















lesions	 of	 central	 nervous	 system,	 with	 the	 total	 number	
diagnosed	annually	outnumbering	all	other	intracranial	tumours	
combined	 [1].	 With	 the	 increasing	 survival	 of	 patients	 with	
extracranial	metastases,	 the	 incidence	 of	 the	 BMs	 in	 the	most	
common	cancers	(lung,	breast,	renal	and	colon)	is	thought	to	be	
rising	[1].	One	important	factor	with	impact	in	the	overall	survival	
(OS)	 for	patients	with	BMs	 is	 the	primary	cancer.	Patients	with	
BMs	with	breast	cancer	have	a	higher	median	OS	when	compared	












Journal of Medical Oncology
2 This article is available in: http://www.imedpub.com/journal-medical-oncology/
a	prognostic	factor	[3,4].	The	more	we	know	about	prognostic	
factors	 for	each	primary	cancer,	 the	better	and	more	 relevant	
treatment	for	BMs	can	be	provided	for	this	group	of	patients.	
There	 are	 several	 therapeutic	 options	 to	 treat	 BMs	 such	 as:	






the	 size	 of	 BM	 as	 a	 prognostic	 factor?	 Is	 there	 an	 association	
between	the	size	of	BMs	and	OS?	Based	on	the	current	data	about	







This	 is	 a	 retrospective,	 single	 center	 study	 (Instituto	 Português	







2006	 to	 2015.	After	 that,	 the	 authors	 reviewed	all	 consecutive	
patients	 and	 selected	 the	 patients	 per	 the	 following	 criteria	
described	below	(Table 1).
Once	eligibility	was	established	we	collected	clinical	information	




BM	 ≥	 3	 cm	 in	 diameter),	 Eastern	 Cooperative	Oncology	Group	
(ECOG)	Performance	Status	(PS),	0	to	4,	 for	each	patient	at	the	
time	 of	 BMs	 diagnosis,	 treatment	 for	 BMs	 with	WBRT	 (yes	 or	
no)	and	date	of	death/last	follow-up.	In	terms	of	treatment	with	
WBRT,	all	patients	were	treated	in	accordance	with	the	Radiation	
Therapy	Oncology	Group	 (RTOG)	 guidelines:	 20	Gy	 to	 30	Gy	 in	
5	sessions	 (4	Gy	per	session)	 to	10	sessions	 (3	Gy	per	session),	
respectively,	in	consecutive	days,	Monday	to	Friday	[7].
Outcomes
The	aim	 is	 to	 verify	 if	 there	 is	 an	association	between	 the	 size	
of	the	BM	(≥	3	cm	in	diameter)	and	the	OS	(in	months)	and,	for	








rank	 test	 for	univariate	 analysis,	 and	Cox	 regression’s	model	 in	
multivariate	survival	analysis.	Univariate	survival	analysis	will	be	
presented	 using	 Kaplan-Meir	 curves	 and	 multivariate	 survival	







in	Table 2. Data	 referring	 to	 sixty-six	 patients	 (40	men	 and	 26	
women)	were	 collected	 from	 2006	 and	 2015.	 The	median	 age	
of	patients	with	BMs	at	 the	time	of	diagnosis	was	63	years	old	
(50-70;	CI	25%-75%).	Melanoma	was	the	most	prevalent	primary	
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cancer	 (76%),	 followed	 by	 head	 and	 neck	 cancer	 (18%)	 and	
sarcoma	(6%).	Melanoma	primary	site	was	unknow	in	5	patients	
and	 from	 skin	 in	 45	 patients.	 The	 primary	 site	 for	 head	 and	
neckcancer	was	oropharynx	 (9	 patients),	 oral	 cavity	 (1	 patient)	
and	unknow	primary	head	andneck	cancer	 (2	patients)..	 In	 the	
group	of	patients	with	sarcoma,	the	primary	location	was	limbs	
(4	patients).	The	distribution	by	ECOG	PS	was	the	following:	45%	







patients	 <65	 years	 had	 an	 increase	 in	 1	 month	 in	 OS	 when	









In	 terms	of	 the	 size	of	BMs,	when	one	metastasis	 is	 ≥	3	 cm	 in	
diameter,	there	is	a	decrease	in	OS=1.3	months	(no	(3.1)	vs	yes	
(1.8),	p<0.05)	(Figure 1). For	this	cohort	of	patients,	there	is	also	
a	 benefit	 in	WBRT	 in	OS	 (no	 (0.8)	 vs	 yes	 (3.3),	 p<0.05)	 (Figure 

















Table 3 Hazard	 Ratio	 (HR)	 of	 all	 covariates	 in	 the	 same	 model	 (Cox-
regression	model).
Figure 1 The	association	between	OS	and	the	size	of	BMs.	
Individuals	 with	 a	 brain	 metastasis	 ≥	 3	 cm	 had	
a	 shorted	 survival	 (decrease	 1.3	 months	 in	 OS,	
p<0.05).
Figure 2 The	association	between	WBRT	and	OS.	The	group	




The	 knowledge	 of	 prognostic	 factors	 in	 patients	 with	 BMs	 is	
important	to	predict	OS	and	to	perform	the	best	treatment	for	
each	 individual	 case.	 There	 are	 already	 very	 well-established	
prognostic	 factors	 such	as	age,	PS,	 the	presence	or	 absence	of	
extracranial	 metastases	 and	 the	 number	 of	 brain	 metastases	
[1,2].
The	aim	of	this	study	was	to	identify	if	the	size	of	BM	could	be	
a	 prognostic	 factor.	 Therefore,	 we	 evaluated	 the	 association	
between	the	size	of	 the	 largest	BM	(≥	3	cm)	with	OS.	The	data	
analysis	did	not	find	that	BMs	bigger	than	3	cm	were	associated	
with	 increased	 mortality,	 after	 controlling	 for	 all	 covariates	
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characteristics	of	 the	patients	 in	 this	 sample.	 Besides	 that,	 the	
ECOG	PS	can	be	under	or	overestimated	by	the	physician	at	the	
time	of	 the	patients'	BMs	diagnosis.	All	 facts	mentioned	above	
can	 promote	 the	 existence	 of	 confounders	 from	many	 sources	
and	 can	 have	 an	 important	 impact	 in	 this	 data	 analysis.	 The	
authors	 encourage	 the	 scientific	 community	 to	 develop	 more	
trials	 to	 evaluate	 not	 only	 the	 association	 between	 the	 size	 of	
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